Treatment of severe Alzheimer's disease in a residential home, nursing home, or geriatric residential setting: evaluation of efficacy and safety of galantamine hydrobromide in a randomised, doubleblind, placebo-controlled study.

Trial Profile

Treatment of severe Alzheimer's disease in a residential home, nursing home, or geriatric residential setting: evaluation of efficacy and safety of galantamine hydrobromide in a randomised, doubleblind, placebo-controlled study.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2010

At a glance

  • Drugs Galantamine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms SERAD
  • Sponsors Janssen Pharmaceutica
  • Most Recent Events

    • 29 Jan 2009 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Planned patient numbers amended from 430 to 415 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top